Prodrug of vitamin D2
Related Products
Technical Support & Resources

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

1-hydroxy Vitamin D2

Item No. 12077

Technical Information
Formal Name
4-methylene-5Z-[2E-[(1R,3aS)-octahydro-7aR-methyl-1R-[1R,4,5-trimethyl-2E-hexen-1-yl]-4H-inden-4-ylidene]ethylidene]-1,3S-cyclohexanediol
CAS Number
54573-75-0
Synonyms
  • Doxercalciferol
  • Hectorol
  • 1-Hydroxyergocalciferol
  • TSA 840
Molecular Formula
C28H44O2
Formula Weight
Purity
≥98%
Formulation
A crystalline solid
DMF: 20 mg/mlDMSO: 20 mg/mlEthanol: 20 mg/mlEthanol:PBS (pH 7.2)(1:2): 0.3 mg/ml
λmax
211, 265 nm
SMILES
C[C@@]12[C@](CC[C@]2([H])[C@H](C)/C=C/[C@H](C)C(C)C)([H])/C(CCC1)=C/C=C3C[C@@H](O)C[C@H](O)C/3=C
InChi Code
InChI=1S/C28H44O2/c1-18(2)19(3)9-10-20(4)25-13-14-26-22(8-7-15-28(25,26)6)11-12-23-16-24(29)17-27(30)21(23)5/h9-12,18-20,24-27,29-30H,5,7-8,13-17H2,1-4,6H3/b10-9+,22-11-,23-12+/t19-,20+,24+,25+,26-,27-,28+/m0/s1
InChi Key
HKXBNHCUPKIYDM-VHKYCACESA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

    Add

    Add

    Add

    Cayman Chemical
    Visit Our Cancer Resource Center
    Find Tools & Resources to Study the Hallmarks of Cancer
    • Cancer cell signaling & regulation
    • Cancer metabolism
    • Tumor microenvironment
    EXPLORE NOW
    Product Description

    1-hydroxy Vitamin D2 is a synthetic prodrug of the active 1,25-dihydroxy vitamin D2 (Item No. 11174), as well as of other active metabolites.1 It is used to suppress the synthesis and secretion of parathyroid hormone in secondary hyperparathyroidism, an action which requires vitamin D receptor.2,3,4 1-hydroxy Vitamin D2 is effective in stimulating bone growth and, in combination therapy with angiotensin receptor blockers, ameliorates albuminuria and glomerulosclerosis associated with diabetic nephropathy.5,6 It also inhibits the growth of certain blastomas and prostate cancer cells.7,8

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Upton, R.A., Knutson, J.C., Bishop, C.W., et alPharmacokinetics of doxercalciferol, a new vitamin D analogue that lowers parathyroid hormone. Nephrol. Dial. Transplant 18, 750-758 (2003).

    2. Frazao, J.M., Chesney, R.W., Coburn, J.W., et alIntermittent oral 1α-hydroxyvitamin D2 is effective and safe for the suppression of secondary hyperparathyroidism in haemodialysis patients. Nephrol. Dial. Transplant 13, 68-72 (1998).

    3. Brown, A.J., Dusso, A.S., and Slatopolsky, E. Vitamin D analogues for secondary hyperparathyroidism. Nephrol. Dial. Transplant. 17(Suppl), 10-19 (2002).

    4. Ritter, C.S., and Brown, A.J. Direct suppression of Pth gene expression by the vitamin D prohormones doxercalciferol and calcidiol requires the vitamin D receptor. J. Mol. Endocrinol. 46(2), 63-66 (2011).

    5. Nguyen-Yamamoto, L., Bolivar, I., Strugnell, S.A., et alComparison of active vitamin D compounds and a calcimimetic in mineral homeostasis. J. Am. Soc. Nephrol. 21, 1713-1723 (2010).

    6. Zhang, Y., Deb, D.K., Kong, J., et alLong-term therapeutic effect of vitamin D analog doxercalciferol on diabetic nephropathy: Strong synergism with AT1 receptor antagonist. Am. J. Physiol. Renal Physiol. 297, F791-F801 (2009).

    7. van Ginkel, P.R., Yang, W., Marcet, M.M., et al1α-Hydroxyvitamin D2 inhibits growth of human neuroblastoma. J. Neurooncol. 85, 255-262 (2007).

    8. Attia, S., Eickhoff, J., Wilding, G., et alRandomized, double-blinded phase II evaluation of docetaxel with or without doxercalciferol in patients with metastatic, androgen-independent prostate cancer. Clin. Cancer Res. 14(8), 2437-2443 (2008).